Navigation Links
Peregrine Pharmaceuticals' Bavituximab Achieves Primary Endpoint in First Stage of Phase II Breast Cancer Study
Date:2/11/2009

--Preliminary Data from Ongoing Study Shows Seven of 14 Evaluable Patients Achieved Objective Tumor Response by the End of Two Treatment Cycles--

--Bavituximab Has Now Produced Positive Early Results in All Three Ongoing Phase II Combination Therapy Cancer Trials--

TUSTIN, Calif., Feb. 11 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) today reported that its lead product candidate bavituximab achieved the pre-specified Stage A primary endpoint in an ongoing Phase II clinical trial in patients with advanced breast cancer. The Phase II trial is an open-label, Simon two-stage design to evaluate the safety and efficacy of bavituximab in combination with the chemotherapy drugs carboplatin and paclitaxel in locally advanced or metastatic breast cancer patients. Fourteen of the 15 patients enrolled in Stage A were deemed evaluable for tumor response, with seven patients achieving an objective response by approximately eight weeks, after completing two treatment cycles. Six of the patients achieved partial tumor responses and one patient achieved a complete tumor response, according to RECIST criteria.

With the Stage A pre-specified primary endpoint achieved, the design of the clinical trial allows for an additional 31 study patients to be enrolled.

"We have now achieved early success in all of our ongoing Phase II bavituximab cancer trials, surpassing our pre-specified primary endpoint criteria for the number of patients achieving an objective tumor response in each of the three clinical studies, " said Steven W. King, president and CEO of Peregrine. "The results reported today reinforce the positive early data seen in our Phase II breast cancer trial assessing bavituximab in combination with docetaxel, as well as the promising early data we reported last week from our Pha
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Positive Results From Peregrine Pharmaceuticals Bavituximab Phase l HCV Trial Presented at AASLD Meeting
2. Peregrine Pharmaceuticals Receives Approval to Begin New Phase II Trial of Bavituximab in Patients With Metastatic Breast Cancer
3. Peregrine Pharmaceuticals Announces Positive Data From Cotara(R) Brain Cancer Trials
4. Data Published in Nature Medicine Highlights Ability of Peregrine Pharmaceuticals Bavituximab to Cure Lethal Virus Infections
5. Peregrine Pharmaceuticals Awarded Broad New U.S. Patent for Anti-Viral Applications of Phospholipid-Targeting Antibodies
6. Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2009
7. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
8. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
9. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
10. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
11. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/21/2014)... Santa Clara, CA (PRWEB) September 22, 2014 ... 2.0 conference it has entered into a joint services ... in South Dakota, to deploy the CareSpan Virtual Clinic ... CareSpan and Avera eCARE plan to deploy their joint ... South Dakota and Wyoming where Avera eCARE is licensed. ...
(Date:9/21/2014)... one of the leading online stores of real and synthetic ... of human hair lace wigs inspired by 6 famous celebrities. ... the latest celebrity hairstyles are. , For people ... hairstyles to choose from: a style of yaki straight lace ... hot ombre red lace wig. People can go to the ...
(Date:9/21/2014)... 21, 2014 More than a quarter of ... fires start in one of two ways. The first type ... properly. The second type of dryer fire occurs when lint ... can also catch fire due to malfunctioning electrical systems so if ... take a look!) Here are some ways that you can ...
(Date:9/21/2014)... Expert witness work is in! That was ... 2014 Expert Witness Fees & Practices Survey. With litigation ... compensation for qualified and credentialed expert witnesses has now ... , The nearly 600 experts surveyed reported earnings ... an increase of 3.2% from ExpertPages’ 2012 survey. They ...
(Date:9/21/2014)... "I wanted to be able to ... sugary, foul-tasting energy drinks," said an inventor from Fresh ... to drink plain, old coffee. That is why I ... developed ENERG CHEWING GUM to provide a healthy energy ... formula contains nutritious vitamins, minerals and antioxidants. It also ...
Breaking Medicine News(10 mins):Health News:Avera eCARE and CareSpan form Collaboration to Deliver “Virtualized” Primary Care in the Dakotas and Wyoming 2Health News:Avera eCARE and CareSpan form Collaboration to Deliver “Virtualized” Primary Care in the Dakotas and Wyoming 3Health News:UniWigs New Arrivals Just In- Human Hair Lace Wigs Inspired By Famous Celebrities 2Health News:Restoration Local Offers Tips to Avoid Dryer Fires 2Health News:Restoration Local Offers Tips to Avoid Dryer Fires 3Health News:ExpertPages 2014 Survey Reports Expert Witness Hourly Fees Record All-Time Highs as Demand for Qualified Experts Continues to Grow 2
... (BRONX, NY) In a study published in The ... Einstein College of Medicine of Yeshiva University have identified ... most likely to develop deadly fungal meningitis, a major ... more than 900,000 HIV-infected people globallymost of them in ...
... in small trial, but there are potential risks , MONDAY, ... running controversy about the purported cholesterol-lowering effects of the centuries-old ... is produced when a yeast, Monascus purpureus , is ... for more than a thousand years as food and medicine. ...
... Inc. (Nasdaq: ELGX ), developer of minimally invasive ... and CEO, is scheduled to deliver a presentation to the ... ET as part of the SMH Capital Small Cap Spotlight ... and an update on the Company,s recently launched products. ...
... N.Y., June 15 SETO Holdings, Inc. (Pink Sheets: ... 100% of the capital stock of Advanced Hearing Centers, ... exchange for the issuance of 70,095,456 shares of common ... services and retails hearing aids from 11 locations in ...
... Just as Congress begins to consider the largest expansion of ... 1965, Hudson Institute will debate the long-term fiscal implications of ... costs will define the long-term fiscal challenge for America. The ... topic of the Hudson panel. , , Visiting Fellow ...
... American Hospital Management Company and HOSPIRIO collaborate to accomplish ... the School of Medicine for Universidad del Azuay to ... , LONGMONT, Colo. and CUENCA, Ecuador, June 15 ... opening of the new facility in Cuenca, Ecuador. The ...
Cached Medicine News:Health News:Predicting fatal fungal infections 2Health News:A Substitute for Those Who Can't Take Statins? 2Health News:A Substitute for Those Who Can't Take Statins? 3Health News:Endologix Announces Live Web Cast of Presentation in SMH Capital Small Cap Spotlight on June 17, 2009 at 4:15 p.m. ET 2Health News:SETO Holdings, Inc. Completes Agreement to Acquire Advanced Hearing Centers, Inc. and Has Disposed of All Existing Business; New Management has been installed 2Health News:Hudson Institute Debates the Long-Term Fiscal Impact of Health Care Reform 2Health News:American Hospital Management Company Announces the Opening of the New HOSPITAL UNIVERSITARIO DEL RIO-HOSPIRIO in Cuenca, Ecuador 2
(Date:9/19/2014)... -- UBM Medica US announces that  OncoTherapy ... oncologists and other clinicians gain a better understanding of ... therapies and immunotherapies, discusses some of the latest news ... Every September, Blood Cancer Awareness Month is ... cancers—helping to increase survival rates and improve the quality ...
(Date:9/19/2014)... , Sept. 19, 2014 Larry J. Merlo ... CVS ), will speak before the National Press Club in ... the company,s recent move to stop selling tobacco products and ... future of health. "Dramatic changes in our health ... providers and government," Merlo has said. "CVS Health has a ...
(Date:9/19/2014)...  Alere Inc. (NYSE: ALR ), a ... today in support of President Barack Obama,s ... global leader in rapid diagnostics for infectious disease, we ... address the serious threat of antibiotic resistance. We look ... initiatives to promote the development of rapid point-of-care tests ...
Breaking Medicine Technology:OncoTherapy Network Highlights National Blood Cancer Awareness Month 2OncoTherapy Network Highlights National Blood Cancer Awareness Month 3OncoTherapy Network Highlights National Blood Cancer Awareness Month 4CVS Health CEO to Address National Press Club on Landmark Decision to Quit Tobacco, Leadership in Health Care Innovation 2CVS Health CEO to Address National Press Club on Landmark Decision to Quit Tobacco, Leadership in Health Care Innovation 3Alere Applauds President's Executive Order Combating Antibiotic-Resistant Bacteria 2
... Inc. and Norgenix Pharmaceuticals, LLC today announced an agreement ... well as US territories and military bases for Femasys, ... to evaluate a woman,s fallopian tubes with standard ultrasound, ... medical device developer of women,s healthcare solutions. Norgenix Pharmaceuticals, ...
... /PRNewswire-Asia-FirstCall/ -- Concord Medical Services Holdings Limited ("Concord Medical" or ... the largest network of radiotherapy and diagnostic imaging centers in ... ADS for its unaudited consolidated financial results for the second ... ended June 30, 2010. Second ...
Cached Medicine Technology:Femasys and Norgenix Announce Distribution Agreement for Groundbreaking New Device for Infertility Diagnosis 2Concord Medical Announces Higher Revenues, Net income, and Earnings per ADS for the Second Quarter 2011 2Concord Medical Announces Higher Revenues, Net income, and Earnings per ADS for the Second Quarter 2011 3Concord Medical Announces Higher Revenues, Net income, and Earnings per ADS for the Second Quarter 2011 4Concord Medical Announces Higher Revenues, Net income, and Earnings per ADS for the Second Quarter 2011 5Concord Medical Announces Higher Revenues, Net income, and Earnings per ADS for the Second Quarter 2011 6Concord Medical Announces Higher Revenues, Net income, and Earnings per ADS for the Second Quarter 2011 7Concord Medical Announces Higher Revenues, Net income, and Earnings per ADS for the Second Quarter 2011 8Concord Medical Announces Higher Revenues, Net income, and Earnings per ADS for the Second Quarter 2011 9Concord Medical Announces Higher Revenues, Net income, and Earnings per ADS for the Second Quarter 2011 10Concord Medical Announces Higher Revenues, Net income, and Earnings per ADS for the Second Quarter 2011 11Concord Medical Announces Higher Revenues, Net income, and Earnings per ADS for the Second Quarter 2011 12
... & Transfer System is a patent-pending disposable, ... procedures simpler for the physician and their ... an office-based technique. LipiVage™ improves upon traditional ... a need to centrifuge, decant or expose ...
... Type B) Injectable Solution, the only Botulinum ... demonstrated in numerous published studies to be ... Delivered as a purified, ready-to-use solution, ... a simpler way to significantly reduce abnormal ...
... is a simple, nonsurgical, physician-administered treatment that ... lines between the brows in people from ... is the only treatment of its type ... (FDA). BOTOX® Cosmetic is a purified ...
Inquire...
Medicine Products: